Cardiovascular effects of cancer therapy
Also called onco-cardiology, cancer cardiotoxicity, chemotherapy heart
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
Cardiotoxicity involves damage to the heart or its function secondary to exposure to toxic substances such as drugs used in chemotherapy, immunotherapy, or radiation.1
Comprehensive echocardiographic assessment is utilized to evaluate cardiac parameters before and after procedures such as allogeneic hematopoietic stem cell transplantation.1 In a cohort of 96 patients, significant changes were observed in diastolic parameters, left ventricular mass, global longitudinal strain, and right ventricular ejection fraction following transplantation.1
The impact of dimethyl sulfoxide on cardiac function during allogeneic hematopoietic stem cell transplantation remains unclear.1
Clinical Significance of Indeterminate Antibody to Hepatitis C in Cancer Patients
Journal of Viral Hepatitis — Pascucci J — Oct 2026
Maximising Cancer Prevention and Early Detection in the Australian Cancer Plan: Where Are We Now and What Should Come Next?
The Medical Journal of Australia — Symonds E — Oct 2026
The Zα domain of ADAR1: emerging roles in cancer biology and evidence as a promising therapeutic target
Cancer Biology & Therapy — Teo J — Oct 2026
Quality Indicators in End‐of‐Life Care for Children With Cancer in Low‐ and Middle‐Income Countries
Cancer Medicine — McNeil M — Oct 2026
Pyroptosis in cancer nanotherapy: Molecular mechanisms and advanced nanosystems (Review)
International Journal of Oncology — Abdulaal W — Oct 2026
Endpoint-specific mortality associated with malignancy among adults with sepsis or septic shock: a systematic review and meta-analysis
Annals of Medicine — Chung H — Oct 2026
Cancer-associated fibroblasts: origins, functional heterogeneity and therapeutic potential
Signal Transduction and Targeted Therapy — Zhou L — Oct 2026
Genetic Testing Station Provides Increased Access to Germline Genetic Testing for Pediatric Oncology Patients
Journal of Genetic Counseling — Hamilton C — Oct 2026
Increased Healthcare Utilization and Differential Outcomes for Pediatric Cancer Versus Non‐Cancer Patients
Cancer Medicine — Chen Y — Oct 2026
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study
The Lancet — Schrag D
403 citations · 2023 · among the most cited on Cardio-oncology
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
The Lancet — ElHafeez S
329 citations · 2025 · among the most cited on Cardio-oncology
cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: Quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II)
Fichtinger-Schepman A
264 citations · 2026 · among the most cited on Cardio-oncology
Radiotherapy toxicities: mechanisms, management, and future directions
The Lancet — Verginadis I
179 citations · 2025 · among the most cited on Cardio-oncology
Long-term care for people treated for cancer during childhood and adolescence
The Lancet — Tonorezos E
107 citations · 2022 · among the most cited on Cardio-oncology
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Harold C. Simmons Comprehensive Cancer Center
h-index 181 · 126k citations
PAX5 modulates vascularization and contributes to neuroendocrine lineage transition during carcinoma progression
Memorial Sloan Kettering Cancer Center
h-index 174 · 148k citations
Examining the role of extrachromosomal DNA in lung cancer
Most-cited researchers publishing on Cardio-oncology.
